Ads
related to: Stelara- COSENTYX® Connect
Sign Up Today For
Support Services.
- Doctor Discussion Guide
Questions to Ask Before Seeing Your
Doctor to Talk About Treatment.
- COSENTYX® Connect
Search results
Stelara biosimilar from Alvotech, Teva approved by FDA
BioPharma Dive via Yahoo Finance· 2 days agoThe FDA cleared Selarsdi for treatment of moderate to severe plaque psoriasis and active psoriatic...
J&J first-quarter revenue misses as Stelara sales disappoint
WSAU Wausau· 3 days ago(Reuters) -Johnson & Johnson reported quarterly revenue below analysts' estimates as sales from its...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
Morningstar· 2 days ago(NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara ...
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara (NYSE:TEVA)
Seeking Alpha· 2 days agoThe FDA has approved Alvotech’s biosimilar of Johnson & Johnson’s (JNJ) Stelara, with Teva hoping to...
Bellwether Health Giant J&J Skids As Psoriasis Blockbuster Drags Top Line
Investor's Business Daily· 2 days agoJohnson & Johnson stock skidded early Tuesday after light sales of blockbuster psoriasis treatment ...
Are your prescription drugs affordable? Colorado board wants feedback on these 2
KDVR Denver via Yahoo News· 1 day agoDENVER (KDVR) — A Colorado board continues reviewing the cost of prescription drugs, and public...
J&J's medical device sales fall short, cancer drugs seen growing
Reuters via Yahoo Finance· 3 days ago(Reuters) -Johnson & Johnson's first-quarter revenue missed Wall Street estimates for medical...
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
Morningstar· 2 days agoAlvotech and Teva Pharmaceuticals said the Food and Drug Administration approved the Selarsdi injection for subcutaneous use as a biosimilar to Stelara for the treatment of ...
Here’s What To Expect From Johnson & Johnson’s Q1
Forbes· 4 days agoJohnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. J&J will likely benefit from higher MedTech sales amid a robust...
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
Zacks via Yahoo Finance· 7 days agoJ&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex...
Ads
related to: Stelara